{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013672","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.929599+00:00","generated_at":"2026-06-16T22:10:20.447620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics Q1 2023 net loss $4.8M, cash $12.7M; completes ReSPECT-LM Phase 1/Part A","bullets":["Completed Part A of ReSPECT-LM Phase 1/2a dose escalation trial for rhenium obisbemeda in leptomeningeal metastases.","Q1 cash $12.7M vs $18.1M at Dec 31, 2022; net loss $0.14/share vs $0.19 prior year.","Operating expenses $5.2M, up from $3.9M YoY, driven by $750K milestone payment to NanoTx Corp and clinical enrollment.","Grant revenue $506K from CPRIT; total grant awards of $20.6M from NIH and CPRIT.","Expects to present ReSPECT-GBM and LM data in H2 2023; planning to initiate pediatric trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013672","json":"https://secwatch.observer/filing/0000950170-23-013672.json","markdown":"https://secwatch.observer/filing/0000950170-23-013672.md","text":"https://secwatch.observer/filing/0000950170-23-013672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/0000950170-23-013672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/pstv-20230420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T22:10:20.447620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76b5cc2a17397421c9a76b841e0b9196aded7d9d","claim":"PLUS THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue $506,000, net income $4.8 million, EPS $(0.14) per share.","evidence_excerpt":"FIRST QUARTER 2023 FINANCIAL RESULTS ▪ The Company’s cash balance was $12.7 million at March 31, 2023, compared to $18.1 million at December 31, 2022. ▪ The Company recognized $506,000 of grant revenue in the first quarter of 2023, which represents the Cancer Prevention & Research Institute of Texas’ (CPRIT) share of costs incurred in the development of rhenium","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/0000950170-23-013672-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$506,000"},{"label":"Net income","value":"$4.8 million"},{"label":"EPS","value":"$(0.14) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}